

## Strongbridge Biopharma plc Announces Presentation at BioEquity Europe 2016

May 5, 2016 9:01 AM ET

DUBLIN and TREVOSE, Pa., May 05, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization of novel therapeutic options, today announced that management will be presenting at BioEquityEurope 2016, taking place May 10-11, 2016 in Copenhagen, Denmark.

A. Brian Davis, chief financial officer of Strongbridge Biopharma, is scheduled to present on Wednesday, May 11 at 12:00 p.m. GMT.

### About Strongbridge Biopharma

Strongbridge Biopharma is a global rare disease biopharmaceutical company focused on the development and commercialization of novel therapeutic options. Strongbridge's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor currently being studied in the global Phase 3 SONICS trial for the treatment of endogenous Cushing's syndrome. Strongbridge's rare endocrine disease franchise also includes COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's disease and neuroendocrine tumors. Both COR-003 and COR-005 have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit [www.strongbridgebio.com](http://www.strongbridgebio.com).

Contacts:

Corporate and Media Relations  
Elixir Health Public Relations  
Lindsay Rocco  
+1 862-596-1304  
[lrocco@elixirhealthpr.com](mailto:lrocco@elixirhealthpr.com)

Investor Relations  
The Trout Group  
Marcy Nanus  
+1 646-378-2927  
[mnanus@troutgroup.com](mailto:mnanus@troutgroup.com)

USA  
900 Northbrook Drive  
Suite 200  
Trevose, PA 19053  
Tel. +1 610-254-9200  
Fax. +1 215-355-7389



Strongbridge Biopharma plc